• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Mage gene-talk-13-01-2012-tartu22-11

Mage gene-talk-13-01-2012-tartu22-11



seminar 13-01-2012

seminar 13-01-2012



Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Mage gene-talk-13-01-2012-tartu22-11 Mage gene-talk-13-01-2012-tartu22-11 Presentation Transcript

    • Biomarkers of prognosis, cancer cellkillers of cytotoxic T lymphocytes (CTL)and autologous tumor antigen (vaccines)arising from MAGE genes Cheng Luo, Ph. D University of Tartu
    • Why MAGE genes?What is MAGE genes?
    • Metagenes associated to survivals Genes up-regulated in NSCLC Gene ID adj. p-value Fold change SPP1 2,76E-17 14,52 MMP1 5,20E-11 10,74 KRT6A 3,85E-05 10,39 KRT17 1,86E-06 9,44 CTHRC1 2,76E-17 7,62 S100A2 2,21E-05 7,44 MMP11 1,29E-11 7,14 TMPRSS4 1,04E-08 6,85 CDC20 1,59E-13 6,82 KRT6B 7,41E-04 6,15 Genes down-regulated in NSCLC Gene ID adj. p-value Fold change SFTPC 7,13E-10 24,43 FCN3 6,77E-17 16,71 FABP4 3,28E-14 13,54 C19ORF59 5,43E-20 12,51 TMEM100 1,65E-21 12,11 CYP4B 1 1,35E-12 11,41 CLIC5 9,37E-21 10,99 SFTPD 4,18E-08 10,75 SFTA2_HUMAN 4,02E-07 10,59 CLEC3B 9,66E-22 10,23 Urgard E. et al. 2011
    • Melanoma Antigen GEne (MAGE), or Cancer/Testis(CT gene) frequently expressed in Melanoma andother cancer cells, MAGE gene was first reported inmelanoma. CT genes include MAGE(s) and others.CT1:MAGEA, CT3:MAGEB,….
    • MAGE/COX2/Nrf2 genesFrom: Ari Ristimäki <ari.ristimaki@helsinki.fi>To: Cheng Luo <luo58@yahoo.com>Sent: Monday, October 24, 2011 9:52 AMSubject: Re: Cluster these genes?Very interesting, you should publish this, Ari from Stockholm (UEGW)
    • Mougiakako D. et al. 2010
    • Andrade VCC et al 2008 (Brazil cohort) percentage of MAGE genes expression in NSCLC (Estonia cohort)706050403020100
    • Gene expression: MAGEB1 (melanoma antigen family B, 1) http://biogps.org
    • Gene expression: MAGEA3(melanoma antigen family A, 3) http://biogps.org
    • Gene expression: MAGEA10(melanoma antigen family A, 10) http://biogps.org
    • Gene expression: MAGEA9 B http://biogps.org
    • Evolutionary History of the CancerImmunity Antigen MAGE Gene Family
    • Evolution (Phylogeny) of Human MAGE genesKatsura et al 2011 (MHD) Can be processed to be epitopes in cancer cells Phase IV (human only) Phase II Phase I
    • 6-7 million years ago Palindrome in MAGE genesReverable palindrome structure play similar roles asmethylation and demethylation
    • MAGE gene is of high CNVCT genes on chromosome X are evolving Most MAGEfaster than those on other chromosomes genes are coded by X- chromosme Y
    • Cell function of MAGE genesXiao TZ et al. 2011 Autoregulation and accuracy of KRAB-MAGEsXiao T. et al. 2011 Plos One
    • MAGEA10: One of the first Cancer antigens
    • From unknown cancer antigen 1999, J. of Immunolo
    • Antibody producing CTL killer
    • The assembly of MHC Class I molecules (endogenous)
    • Group Leader Pierre van der Bruggen MAGE gene was designated in 1991 Contact Pierre van der Bruggen de Duve Institute, Université catholique de Louvain, and Ludwig Institute for Cancer Research LICR - B1.74.03, Avenue Hippocrate 74, B-1200 Brussels phone (direct) : 32 (0)2 764 74 31 fax : 32 (0)2 792 94 05 e-mail: Pierre van der Bruggen Tumor immunology, or cancer immunotherapy start: van der Bruggen P, et al 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.. Science. 1991 Dec 13;254(5038):1643-7Barker PA, Salehi A.The MAGE proteins: emerging roles in cell cycle progression, apoptosis, andneurogenetic disease. J Neurosci Res. 2002 Mar 15;67(6):705-12.Since the identification of the first MAGE gene in 1991, the MAGE family has expandeddramatically, and over 25 MAGE genes have now been identified in humans. The focus of studies onthe MAGE proteins has been their potential for cancer immunotherapy, as a result of the finding thatpeptides derived from MAGE gene products are bound by major histocompatibility complexes andpresented on the cell surface of cancer cells. However, the normal physiological role of MAGE proteinshas remained a mystery. Recent studies are now beginning to provide insights into MAGEgenefunction. Necdin acts as a cell cycle regulatory protein and plays a key role in the pathogenesis ofPrader-Willi syndrome, a neurogenetic disorder. MAGE-D1, identified as a binding partner for the p75neurotrophin receptor, the apoptosis inhibitory protein XIAP, and Dlx/MSX homeodomainproteins, blocks cell cycle progression and enhances apoptosis. This review provides an overview of thehuman MAGE genes and proteins, summarizes recent findings on their cellular roles, and provides abaseline for future studies on this intriguing gene family.
    • TIB and MAGE-B2 antibody in serum
    • http://www.immunocore.com/technology/specificity/ This video was filmed over a period of 11 hours and demonstrates the specificity of the MAGE-A3 ImmTAC. The target cancer cells with HLA-A1 and the MAGE A3 antigen are dyed red; control cells which are also HLA-A1 but which do not have the antigen MAGE A3 are dyed green. CD8+ T cells are unstained and appear grey. When the MAGE specific ImmTAC is added to the experiment at 50pM concentration all of the target cells (red) are killed by the T cells whilst the innocent bystanders (green) are unaffected.
    • Cancer cells loadedanti-tumor with MHC I andT cells in MAGE3Amelanoma A CTL clone (pulsedpatients by MAGE3A) that recognize MAGE3 ACTLisolatedfromtumors andexpanded Cancer cell without MHCfor several or MAGE3Aweeks invitro, lysedautologousmelanomacells Start of the video
    • End of the video
    • Non-specific T cells (blue) recognise and kill target melanoma cells (red) but ignore non-target cells (green) in the presence of the drug, IMCgp100. http://www.immunocore.com/pipeline/imcgp100/
    • For antibody (or humoral) mediated immunology
    • MAGE antigen (epiopes) presented by CD8+ T-cells TCR
    • >100 million TCR5.3. MAGE-A3 vaccineMAGE-A3 is a tumor-associated antigen that is notexpressed in most normal cells [31,61]. Approximately 35–50% of lung cancers express MAGE-A3, and expression hasbeen associated with poor prognosis [31]. This providedthe rationale for the development of a TCV comprisingMAGE-A3 recombinant protein combined with the AS02Bimmunoadjuvant. Mellstedt H. et al 2011
    • Source of tumor antigens:MAGE Epitopes http://www.cancerimmunity.org/peptidedatabase/tumorspecific.htm
    • MAGE antigens: From nuclearprotein to epitopes
    • By experimentalhttp://www.cancerimmunity.org/peptidedatabase/tumorspecific.htm
    • Immunotherapy database (successful, or the peptide with potential because ofhigh stringency):http://www.cancerimmunity.org/peptidedatabase/tumorspecific.htm By experimental
    • Table 3. Differentiation antigens By experimental
    • Table 4. Antigens overexpressed in tumors By experimental
    • Potential epitopes of HLA-A (10AA) of MAGEA10 for lung cancer patiensts by BIMAS algorithms BioInformatics & Molecular Analysis Section (BIMAS)
    • MAGE antigens for HLA-II were also determined (The A, B, C, E, F, and G genes belong to MHC class I, six D genes belong to class II)HLA II alsoin CTA, orMAGEantigensMAGE genescan beimprinted
    • An alignment of primate MAGE-A amino acid sequences for an epitope coding region. In humans, based onreferences (1–16), MAGE-A epitopes for HLA alleles are denoted by squares (magenta; HLA class Ι, light blue; HLAclass II). HLA alleles that recognize each epitope are indicated in parallel below. Among 13 amino acid substitutionsbetween MAGE-A3 and -A6, 11 substitutions marked by stars occur in the alignment whereas two substitutions(P303L, A308V) occured outside of the region. Among the 11 substitutions, ten that contribute to the production ofepitopes for different HLA alleles(E115K, D156L, L175V, T199A, L201F, V205I, K211R, D249H/D249Y, L279V/L279I, H298R) are indicated by green stars.The other substitution within this region (indicated by a blue star; F239L) does not contribute to the production ofepitopes of MAGE-A3 and -A6 [53–68].
    • Correlation of MAGE gene expression and survivals
    • 2 12 4 8 0 6 10 lung, squamous cell carcinoma Lung-Ca 617 lung, adenocarcinoma Lung-Ca 674 lung, squamous cell carcinoma Lung-Ca 619 lung, adenocarcinoma Lung-Ca 1104lung, squamous cell carcinoma Lung-Ca 746 lung, adenocarcinoma Lung-Ca 572 Lung Cancerlung, squamous cell carcinoma Lung-Ca 576lung, squamous cell carcinoma Lung-Ca 268 lung, large cell carcinoma Lung-Ca 735 lung, adenocarcinoma Lung-Ca 743lung, squamous cell carcinoma Lung-Ca 1086 lung, adenocarcinoma Lung-Ca 814 MAGEA3 expression lung, adenocarcinoma Lung-Ca 481 lung, adenocarcinoma Lung-Ca 721 lung, adenocarcinoma Lung-Ca 562lung, squamous cell carcinoma Lung-Ca 554 lung, adenocarcinoma Lung-Ca 865 lung, adenocarcinoma Lung-Ca 670 lung, squamous cell carcinoma Lung-Ca 777 lung, adenocarcinoma Lung-Ca 1102 Determinant of Worse Survival in Stage IA Non-Small Cell lung, squamous cell carcinoma Lung-Ca 591 Port JL et al. 2009, MAGE-A3 Expression is an Independent lung, normal Lung Normal 1050 lung, normal Lung Normal 567lung, squamous cell carcinoma Lung-Ca 265lung, squamous cell carcinoma Lung-Ca 582 lung, normal Lung Normal 1054 lung, adenocarcinoma Lung-Ca 729 lung, adenocarcinoma Lung-Ca 593lung, squamous cell carcinoma Lung-Ca 494lung, squamous cell carcinoma Lung-Ca 1087 lung, normal Lung Normal 551 lung, adenocarcinoma Lung-Ca 715 lung, normal Lung Normal 549 lung, carcinoma Lung-Ca 863lung, squamous cell carcinoma Lung-Ca 625 lung, normal Lung Normal 548 lung, adenocarcinoma Lung-Ca 820lung, squamous cell carcinoma Lung-Ca 560lung, squamous cell carcinoma Lung-Ca 676 lung, large cell carcinoma Lung-Ca 578
    • Example of MAGEexpression isassociated to goodprognosisGrau et al., MAGE-A1expression is associatedwith good prognosis inneuroblastoma tumors, J. of Cancer Researchand ClinicOncology, 2009
    • Example of MAGEexpression isassociated to goodprognosis
    • Condomines et al. 2007, J. of Immunology
    • MAGE Expressions Mediated by Demethylation of MAGE Promoters Induce Progression of Non-small Cell Lung Cancer YANAGAWA N. et al. 2011Correlation between MAGE expression and overall survival of 67 NSCLC patients using the Kaplan-Meier method.The patients with any expression had poorer prognosis than those with no expression.
    • Boehmer et al. 2011, MAGE-C2/CT10 Protein Expression Is anIndependent Predictor of Recurrence in Prostate Cancer, PLos One
    • Gure A. et al. 2005, Clinic CancerResearch,Survival of patients with NSCLCstratified according to CT-Xexpression and pathologic stage.Distributions were estimated usingthe Kaplan-Meier method. Tick marksrepresent the time of last follow-upfor patients who remained alive.Representative series. A, high-level MAGE-A3 expression inadenocarcinoma patients of stage I(P = 0.04). B, high level NY-ESO-1 expression in adenocarcinomapatients of stage II (P =0.02). C, SSX2 expression in patientswith adenocarcinoma of stage III (P =0.05).
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • Estonia cohort By Krista Fischer & Reedik Mägi
    • The barrier of immunotherapy
    • Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine and Pierre vander Bruggen * 2011 Immune Suppression in Tumors as aSurmountable Obstacle to Clinical Efficacy of Cancer Vaccines
    • Immune activation in favor Cytokines influence T-helpers Immune suppressive in favorPanel A: Immune-mediated tumour killing requires a Th1 microenvironment. In the presence of Th1 cytokines, tumours upregulate MHC I and co-stimulatory molecules necessary for cytolytic T-cells (CTL) to recognise and kill the tumours. In addition, the inflammatory Th1 environment cannon-specifically activate T-cells to kill tumours through FasL and TRAIL effector molecules. Panel B: Tumours condition the microenvironment tohave a dominant Th2-bias as a strategy to escape immune mediated attack. In the presence of Th2 cytokines, tumours down-regulate MHC and co-stimulatory molecules, attract suppressor cells such as Treg and myeloid suppressors which suppress killer cell function. The Th2 environmentdown-regulates co-stimulatory molecules on APC which serves to anergise any Th1 cells that may infiltrate the tumour, whether as a naturalimmune response or through tumour vaccination strategies. Therefore, strategies to boost Th1 immunity alone are not sufficient to mediate anti-tumour immunity. Sustained Th1 cytokine production is required in the tumour microenvironment.
    • CD8 –T (for MHC I) cells are needed MDSC: myeloid-derived suppressor cells
    • Some successfulexamples even though the obstacles of immunotherapy in cancer medication because of immunosuppressive environmentWieërs, der Bruggen et al2011, Immune Suppression in Tumorsas a Surmountable Obstacle toClinical Efficacy of Cancer Vaccines
    • patients who received at30patients least four vaccinations with ALVAC (attenuated 1/30 canarypox virus ) cured miniMAGE-1/3. Metastasis at 8/30 study entry: Dark gray, measurable metastases at study entry; light gray, metastasis removed before study. n-visc., non- visceral distant metastasis; visc., visceral metastasis; C, cutaneous; S, subcutaneous; L, lymph node; Lu, lung; O, other visceral localization; Prog., progression; Reg., regression. Baren et al 2005
    • Frequencies and target antigens of antitumor CTLs from patient EB81.The frequencies of antitumor and anti-vaccineCTLps are indicated in the top. Frequencies ofantitumor CTLps were measured by MLTCwith a tumor cell line derived from the invaded Pierre G. Coulie, de Duve Institute,lymph node, whereas those of anti–MAGE-3.A1 Université catholique de Louvain, Avenue Hippocrate 74, UCL 7459, B-120and anti–MAGE-C2336–344 CTLps were Brussels, Belgium.measured by clonotypic PCR. The bottom Tel: 32(2)7647581, Fax: 32(2)7647590, Email: pierre.coulie@uclouvain.bepanels represent antitumor CTL clones withdifferent numbers for each TCR sequence andthe occurrence of repeated clones. Most ofthese CTL clones were derived fromlymphocytes collected in September 1999 andMarch 2000 and were stimulated in autologousMLTC. Additional CTL clones were derivedfrom lymphocytes collected in October 2000by stimulation with MAGE-C2 peptides andidentification of the positive microcultureswith the appropriate tetramer. For peptideMAGE-C2336–344, 15 additional CTL clones were TCRobtained. 14 turned out to be the CTL 16clonotype, whereas one, CTL 40, had anotherTCR. A similar experiment performed withMAGE-C2191–200 revealed a new highly repeatedclonotype, CTL 41. Germeau C et al. J Exp Med 2005;201:241-248
    • Current Objectives:Dr. Krista Frisher: Kaplan Meier survival curve based on MAGE genesexpression in NSCLC of Estonia cohort. An independent biomarker ? After this, epitope screening? Stringency testing? 2D and 3D MAGE gene ? Serum title of living subjects? ?
    • gspagnoli-at-uhbs.chDepartment of BiomedicineUniversity Hospital BaselHebelstrasse 20CH - 4031 BaselOffice phone+41 61 265 23 78Office fax+41 61 265 30 90
    • Expression of MAGE-A Cancer/Testis Antigens in Esophageal Squamous Cell Carcinomas J. HAIER1, M. OWZCARECK1, U. GULLER3, G. C. SPAGNOLI3, H. BüRGER2, N. SENNINGER1 and TH. KOCHER4 1Molecular Biology Laboratory, Department of General Surgery and 2Department of Pathology, University Hospital, Münster, Germany;3Institute for Surgical Research and Hospital Management, University Hospital Basel; 4Department of General, Visceral and Vascular Surgery, Kantonsspital, Baden, Switzerland
    • Bujas T et al. European Journal of Histochemistry 2011; volume 55:e7Immunohistochemical expression of MAGE–A 3/4 and NY-ESO-1 in esophageal squamous cell carcinoma and lymph node metastasis. Expression of A) MAGE-A 3/4 andB) NY-ESO-1 in a primary tumor was cytoplasmic and limited to tumor cells. Similar immunohistochemicalreaction for C) MAGE-A 3/4 and D) NY-ESO-1 was also observed in corresponding lymph node metastases.
    • Normally MAGE genes are highly hypermethylated
    • Thank you for your attention!